Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

CNBC host Jim Cramer continues to pound the table on Eli Lilly’s (LLY) stock. The host of the TV show “Mad Money” continues to be a cheerleader for LLY stock, saying repeatedly that the pharmaceutical ...

Shares of Johnson & Johnson climbed 6.8% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for their biggest one-day gain and best postearnings reaction since ...

Eli Lilly’s stock closed at $771.75, slipping 3.45% and lagging the broader market. The company’s shares fell despite outperforming the medical sector over the past month. Analysts eagerly await its ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's policies. Health care stocks can often be a solid defensive play in an ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

According to TipRanks.com, Lebowitz is a 4-star analyst with an average return of 4.4% and a 55.7% success rate. Lebowitz covers the Healthcare sector, focusing on stocks such as Arrowhead ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Cantor Fitzgerald cut Eli Lilly’s FY2025 earnings forecast from $21.91 to $21.76 per share. Eli Lilly reported $3.34 per ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.